Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Published: 17th January 2018
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Blood is the most extensively studied body fluid and, because it contains circulating tumour cells (CTCs) and circulating tumour‐derived cell‐free DNA (ctDNA), it may represent a liquid biopsy for cancer. Methods for enrichment and detection of CTCs and ctDNA, their clinical applications and future opportunities in gastrointestinal cancers were the focus of this review.
The PubMed database was searched for literature up to 24 June 2017, with a focus on the past 10 years. Identified articles were further scrutinized for relevant references. Articles were those in English relating to colorectal, gastric and pancreatic cancer.
Both CTCs and ctDNA are in low abundance compared with other cellular components of blood, but effective enrichment and highly sensitive techniques are available for their detection. Potential clinical applications of these liquid biopsies include screening, prognostic stratification, therapy administration, monitoring of treatment effect or resistance, and surveillance. Liquid biopsies provide opportunities to reduce the need for invasive tissue sampling, especially in the context of intratumoral heterogeneity and the need for tumour genotyping.
Liquid biopsies have applications in gastrointestinal cancers to improve clinical decision‐making.Full text
You may also be interested in
Authors: M. Del Chiaro, K. Søreide
Authors: H. Elfeki, H. M. Larsen, K. J. Emmertsen, P. Christensen, M. Youssef, W. Khafagy et al.
Notes: Sigmoid resection associated with bowel dysfunction
Authors: J. Segelman, C. Buchli, A. Svanström Röjvall, P. Matthiessen, S. Arver, M. Bottai et al.
Notes: Ovarian androgens reduced
Multicentre study of the prognostic impact of preoperative bodyweight on long‐term prognosis of hepatocellular carcinoma.
Authors: J. J. Yu, F. Shen, T. H. Chen, L. Liang, J. Han, H. Xing et al.
Notes: BMI matters
Randomized clinical trial
Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. BJS 2018; 105: 1417-1425.
Authors: E. Akgun, C. Caliskan, O. Bozbiyik, T. Yoldas, M. Sezak, S. Ozkok et al.
Notes: Worth waiting
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practise makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Authors: G. Marchegiani, S. Andrianello, G. Morbin, E. Secchettin, M. D'Onofrio, R. De Robertis et al.
Notes: Duct dilatation no risk alone
Authors: M. Baré, L. Mora, N. Torà, M. J. Gil, I. Barrio, P. Collera et al.
Notes: Defines risk
Authors: M. Ishimaru, H. Matsui, S. Ono, Y. Hagiwara, K. Morita, H. Yasunaga et al.
Notes: Preoperative dental care reduces postoperative pneumonia
Prognostic implications of MRI‐detected lateral nodal disease and extramural vascular invasion in rectal cancer.
Authors: D. P. Schaap, A. Ogura, J. Nederend, M. Maas, J. S. Cnossen, G. J. Creemers et al.
Notes: Defines recurrence risk
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk